Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
Add more filters










Publication year range
1.
Sr Care Pharm ; 35(11): 482-483, 2020 Nov 01.
Article in English | MEDLINE | ID: mdl-33121569

ABSTRACT

In a country with 1.3 billion population and about 1,000 universities and more than 50,000 higher education institutions and enrollment of 30 million students and a diverse demography, to find a single solution that can keep the teaching and learning process continued was a mammoth task. The focus was on engaging the students and completing the academic sessions. Having crossed the phase of teaching and learning, the institutions are now grappling as to how the examinations and progression of these students be considered. Learning from global experiences and a bit of innovation, this too has been overcome with methodologies that would have been unacceptable earlier. The challenge presently is the preparedness of higher education in the post pandemic period.


Subject(s)
Education, Pharmacy , Humans , Students , Universities
2.
Sci Pharm ; 80(4): 789-823, 2012.
Article in English | MEDLINE | ID: mdl-23264933

ABSTRACT

2-Mercaptobenzothiazoles are an important class of bioactive and industrially important organic compounds. These compounds are reported for their antimicrobial and antifungal activities, and are subsequently highlighted as a potent mechanism-based inhibitor of several enzymes like acyl coenzyme A cholesterol acyltransferase, monoamine oxidase, heat shock protein 90, cathepsin D, and c-Jun N-terminal kinases. These derivatives are also known to possess antitubercular, anti-inflammatory, antitumor, amoebic, antiparkinsonian, anthelmintic, antihypertensive, antihyperlipidemic, antiulcer, chemoprotective, and selective CCR3 receptor antagonist activity. This present review article focuses on the pharmacological profile of 2-mercaptobenzothiazoles with their potential activities.

3.
Curr Drug Deliv ; 9(4): 405-13, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22520069

ABSTRACT

In patients with diabetes, hyperglycemia is known to promote high levels of diacylglycerol which activates protein kinase C (PKC) in the vascular tissues and leads to the production of vascular endothelial growth factor (VEGF) in the retina. PKC activation and increased concentration of VEGF are likely to play a key role in diabetic microvascular complications, particularly change in vascular permeability, inflammation, fluid leakage and ischemia in the retina. PKC comprises a super family of isoenzymes that is activated in response to various stimuli. The PKC family consists of 12 isomers that possess distinct differences in structure, substrate requirement, expression and localization. PKC isomer selective inhibitors and VEGF trap are likely to be new therapeutics, which can delay the onset or stop the progression of diabetic vascular disease. A new promising therapy for diabetic retinopathy is undergoing Phase III trials, in which they proposed to target PKC ßII isomer using Ruboxistaurin by oral administration. Besides retina, PKC ßII isomer is found in higher concentration in brain, spleen, etc. So, oral targeting may be a questionable approach since generalized inhibitors may prove toxic in the treatment of diabetic retinopathy and ocular delivery may be a better alternative approach.


Subject(s)
Diabetic Retinopathy/drug therapy , Indoles/administration & dosage , Indoles/pharmacokinetics , Maleimides/administration & dosage , Maleimides/pharmacokinetics , Protein Kinase C/antagonists & inhibitors , Protein Kinase C/metabolism , Administration, Oral , Animals , Clinical Trials, Phase III as Topic , Diabetic Retinopathy/complications , Diabetic Retinopathy/metabolism , Enzyme Inhibitors/administration & dosage , Enzyme Inhibitors/pharmacokinetics , Humans , Hyperglycemia/complications , Molecular Targeted Therapy , Vascular Endothelial Growth Factor A/metabolism
4.
Acta Chim Slov ; 59(4): 739-48, 2012 Dec.
Article in English | MEDLINE | ID: mdl-24061354

ABSTRACT

Several 2-mercaptobenzothiazole derivatives 5a-i containing 1,2,4-triazole moiety incorporating two additional substituents were synthesized. All the newly synthesized compounds were tested for in vitro activity against certain strains of bacteria such as Enterococcus faecalis, Bacillus coagulans, Pseudomonas aeruginosa, Escherichia coli and Candida albicans. Compound 5a showed significant activity against the Gram-negative bacteria Escherichia coli. Compounds 5a-i were also screened for their antifungal activity against Candida albicans and compounds 5a, 5b, 5d and 5g displayed significant activity against this fungus. Some of these compounds were evaluated for their in vivo anti-inflammatory activity, acute toxicity and ulcerogenic actions. Tested compounds 5g and 5h showed significant anti-inflammatory activity and significant gastrointestinal protection compared to the standard drug diclofenac sodium. Molecular modeling studies of the synthesized compounds are presented.

5.
Nanomedicine ; 6(1): 144-52, 2010 Feb.
Article in English | MEDLINE | ID: mdl-19446656

ABSTRACT

Tacrine-loaded chitosan nanoparticles were prepared by spontaneous emulsification. The particle size and zeta potential was determined by scanning probe microscopy and Zetasizer, respectively. The prepared particles showed good drug-loading capacity. The in vitro release studies showed that after the initial burst, all the drug-loaded batches provided a continuous and slow release of the drug. Coating of nanoparticles with Polysorbate 80 slightly reduced the drug release from the nanoparticles. Release kinetics studies showed that the release of drug from nanoparticles was diffusion-controlled, and the mechanism of drug release was Fickian. The biodistribution of these particles after intravenous injection in rats showed that of nanoparticles coated with 1% Polysorbate 80 altered the biodistribution pattern of nanoparticles. FROM THE CLINICAL EDITOR: In this paper, chitosan nanoparticles are investigated in a pre-clinical study as an optimized delivery system for tacrin, a drug with potential significance in Alzheimer's disease. The preparation showed optimal pharmacokinetic characteristics in a rat model.


Subject(s)
Alzheimer Disease/drug therapy , Chitosan/chemistry , Drug Delivery Systems/methods , Nanoparticles/chemistry , Tacrine/administration & dosage , Tacrine/therapeutic use , Animals , Chitosan/administration & dosage , Drug Stability , Injections, Intravenous , Kinetics , Microscopy, Scanning Probe , Nanoparticles/administration & dosage , Particle Size , Rats , Rats, Wistar , Tacrine/pharmacokinetics , Tissue Distribution
7.
J Neurosci Methods ; 177(2): 427-33, 2009 Mar 15.
Article in English | MEDLINE | ID: mdl-19041670

ABSTRACT

Alzheimer's disease (AD) is a progressive degenerative disorder of the brain characterized by a slow, progressive decline in cognitive function and behavior. As the disease advances, persons have a tough time with daily tasks like using the phone, cooking, handling money or driving the car. AD affects 15 million people worldwide and it has been estimated that AD affects 4.5 million Americans. Tacrine is a reversible cholinesterase inhibitor used for treating mild to moderate AD. In the present study, an attempt was made to target the anti-Alzheimer's drug tacrine in the brain by using magnetic chitosan microparticles. The magnetic chitosan microparticles were prepared by emulsion cross-linking. The formulated microparticles were characterized for process yield, drug loading capacity, particle size, in vitro release, release kinetics and magnetite content. The particle size was analyzed by scanning electron microscope. The magnetite content of the microparticles was determined by atomic absorption spectroscopy. For animal testing, the microparticles were injected intravenously after keeping a suitable magnet at the target region. The concentrations of tacrine at the target and non-target organs were analyzed by HPLC. The magnetic chitosan microparticles significantly increased the concentration of tacrine in the brain in comparison with the free drug.


Subject(s)
Alzheimer Disease/drug therapy , Chitosan/administration & dosage , Drug Delivery Systems/methods , Nanoparticles/administration & dosage , Tacrine/administration & dosage , Animals , Biocompatible Materials/administration & dosage , Chitosan/pharmacokinetics , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/pharmacokinetics , Dose-Response Relationship, Drug , Drug Delivery Systems/instrumentation , Ferrosoferric Oxide/administration & dosage , Ferrosoferric Oxide/pharmacokinetics , Injections, Intravenous/methods , Magnetics/methods , Male , Microscopy, Electron, Scanning , Nanoparticles/ultrastructure , Rats , Rats, Wistar
8.
Drug Deliv ; 15(7): 429-35, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18712620

ABSTRACT

Sustained release (SR) matrix tablets of dextromethorphan hydrobromide were prepared by wet granulation using hydroxypropyl methyl cellulose (HPMC-K-100 CR) as the hydrophilic rate controlling polymer. The effect of the concentration of the polymer and different fillers on the in vitro drug release rate was studied. The studies indicated that the drug release can be modulated by varying the concentration of the polymer and the fillers. A complete cross-over bioavailability study of the optimized formulation of the developed sustained tablets and marketed immediate release tablets was performed on six healthy male volunteers. The extent of absorption of drug from the SR tablets was significantly higher than that for the marketed dextromethorphan hydrobromide tablet because of lower elimination rate and longer half-life.


Subject(s)
Antitussive Agents/pharmacokinetics , Dextromethorphan/pharmacokinetics , Adult , Antitussive Agents/administration & dosage , Antitussive Agents/blood , Biological Availability , Chromatography, High Pressure Liquid , Cross-Over Studies , Delayed-Action Preparations , Dextromethorphan/administration & dosage , Dextromethorphan/blood , Drug Compounding , Drug Stability , Excipients/chemistry , Humans , Hypromellose Derivatives , Kinetics , Male , Methylcellulose/analogs & derivatives , Methylcellulose/chemistry , Tablets
9.
Eur J Pharm Biopharm ; 70(1): 75-84, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18472255

ABSTRACT

The purpose of the present study was to investigate the possibility of targeting an anti-Alzheimer's drug tacrine in the brain using polymeric nanoparticles. Rats obtained 1mg/kg of tacrine by intravenous injection in the form of three preparations: (1) a simple solution in phosphate buffered saline, (2) bound to poly(n-butylcyanoacrylate) nanoparticles, and (3) bound to poly(n-butylcyanoacrylate) nanoparticles coated with 1% polysorbate 80 (Tween 80). After 1h of post injection the rats were killed by decapitation and tacrine concentration in brain, liver, lungs, spleen and kidneys was analyzed by HPLC. A higher concentration of drug tacrine was observed in liver, spleen and lungs with the nanoparticles in comparison to the free drug. The accumulation of drug tacrine in the liver and spleen was reduced, when nanoparticles were coated with 1% polysorbate 80. In the brain a significant increase in tacrine concentration was observed in the case of poly(n-butylcyanoacrylate) nanoparticles coated with 1% polysorbate 80 compared to the uncoated nanoparticles and the free drug. In conclusion, the present study demonstrates that the brain concentration of intravenously injected tacrine can be enhanced by binding to poly(n-butylcyanoacrylate) nanoparticles, coated with 1% the nonionic surfactant polysorbate 80.


Subject(s)
Brain/metabolism , Cholinesterase Inhibitors/metabolism , Drug Carriers , Enbucrilate/chemistry , Nanoparticles , Polysorbates/chemistry , Surface-Active Agents/chemistry , Tacrine/metabolism , Animals , Blood-Brain Barrier/metabolism , Chemistry, Pharmaceutical , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/chemistry , Drug Stability , Injections, Intravenous , Kinetics , Particle Size , Rats , Rats, Wistar , Solubility , Tacrine/administration & dosage , Tacrine/chemistry , Technology, Pharmaceutical/methods
10.
Brain Res ; 1200: 159-68, 2008 Mar 20.
Article in English | MEDLINE | ID: mdl-18291351

ABSTRACT

Alzheimer's disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of activities of daily living, and a variety of neuropsychiatric symptoms and behavioral disturbances. Alzheimer's disease affects 15 million people worldwide and it has been estimated that Alzheimer's disease affects 4.5 million Americans. Rivastigmine is a reversible cholinesterase inhibitor used for the treatment of Alzheimer's disease. Central nervous system drug efficacy depends upon the ability of a drug to cross the blood-brain barrier and reach therapeutic concentrations in brain following systemic administration. The clinical failures of most of the potentially effective therapeutics to treat the central nervous system disorders are often not due to a lack of drug potency but rather shortcomings in the method by which the drug is delivered. Hence, considering the importance of treating Alzheimer's disease, we made an attempt to target the anti-Alzheimer's drug rivastigmine in the brain by using poly(n-butylcyanoacrylate) nanoparticles. The drug was administered as a free drug, bound to nanoparticles and also bound to nanoparticles coated with polysorbate 80. In the brain a significant increase in rivastigmine uptake was observed in the case of poly(n-butylcyanoacrylate) nanoparticles coated with 1% polysorbate 80 compared to the free drug. In conclusion that the present study demonstrates that the brain concentration of intravenously injected rivastigmine can be enhanced over 3.82 fold by binding to poly(n-butylcyanoacrylate) nanoparticles coated with 1% nonionic surfactant polysorbate 80.


Subject(s)
Alzheimer Disease/drug therapy , Drug Delivery Systems/methods , Enbucrilate/therapeutic use , Nanoparticles/chemistry , Phenylcarbamates/administration & dosage , Polysorbates/therapeutic use , Animals , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/metabolism , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/pharmacokinetics , Dose-Response Relationship, Drug , Enbucrilate/chemistry , Male , Nanoparticles/administration & dosage , Phenylcarbamates/pharmacokinetics , Polysorbates/chemistry , Rats , Rats, Wistar , Rivastigmine , Surface-Active Agents/chemistry , Surface-Active Agents/therapeutic use , Up-Regulation/physiology
11.
Acta Pol Pharm ; 64(1): 17-26, 2007.
Article in English | MEDLINE | ID: mdl-17665846

ABSTRACT

A variety of novel 4-[(4'-substituted phenyl)-6-(4"-hydroxyphenyl)-2-substituted imino] pyrimidines were synthesized by reacting 4-(4'-substituted phenyl)-6-(4"-hydroxyphenyl)-2-aminopyrimidines with different substituted aromatic aldehydes, with coumarin and with chloroisatin. The 4-(4'-chlorophenyl)-6-(4"-hydroxyphenyl)-2-aminopyrimidines were synthesized by reacting 3-(4'-substituted phenyl)-1-(4"-hydroxyphenyl)-2-propen-1-ones with guanine hydrochloride. The 3-(4'-substituted phenyl)-1-(4"-hydroxyphenyl)-2-propen-1-ones were synthesized by reacting 4-hydroxyacetophenone with different para substituted aromatic aldehydes. Spectral data (IR, NMR, and mass spectra) confirmed the structures of the synthesized compounds. The synthesized compounds were investigated for their antiviral, antituberculostic and antibacterial activities. The results indicated that the synthesized compounds have mild to potent activities with reference to their appropriate reference standards. However, mechanism related studies could be carried out to predict the structure activity relationship for all the compounds.


Subject(s)
Anti-Bacterial Agents/chemical synthesis , Antitubercular Agents/chemical synthesis , Antiviral Agents/chemical synthesis , Pyrimidines/chemical synthesis , Anti-Bacterial Agents/chemistry , Anti-Bacterial Agents/pharmacology , Antitubercular Agents/chemistry , Antitubercular Agents/pharmacology , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Antiviral Agents/toxicity , Dose-Response Relationship, Drug , Magnetic Resonance Spectroscopy , Mass Spectrometry , Microbial Sensitivity Tests , Pyrimidines/administration & dosage , Pyrimidines/chemistry , Pyrimidines/pharmacology , Pyrimidines/toxicity , Reference Standards , Spectrophotometry, Infrared , Structure-Activity Relationship
12.
Fitoterapia ; 78(2): 120-4, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17169502

ABSTRACT

The Celastrus oil, extracted from seeds of Celastrus paniculatus tested at 2 dose levels (1 and 1.5 g/kg), exhibited significant anxiolytic activity and did not produce tolerance. The non-sedative nature and reversal of buspirone induced behaviour (in open field exploration) point to the serotonergic mechanism underlying the anxiolysis, inspiring further research.


Subject(s)
Anti-Anxiety Agents/pharmacology , Behavior, Animal/drug effects , Celastraceae , Phytotherapy , Plant Oils/pharmacology , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/therapeutic use , Anxiety Disorders/drug therapy , Dose-Response Relationship, Drug , Female , Male , Models, Animal , Plant Oils/administration & dosage , Plant Oils/therapeutic use , Rats , Rats, Wistar , Seeds
13.
Patient Educ Couns ; 54(1): 55-60, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15210260

ABSTRACT

The primary aim of this study was to assess the impact of patient medication counseling by comparing the levels of patient's medication knowledge and adherence achieved by medication counseling in an outpatient clinic. Ninety patients were randomized in the ratio of 1:2 into either counseled or usual care group. Their medication knowledge was assessed by a questionnaire and adherence was assessed by pill count method and self-assessment by the patients. Their medication knowledge was assessed at baseline and during their subsequent appointments. The average medication knowledge score of the counseled group versus usual care group was 13.82+/-1.8064 and 11.78+/-3.5037. Compliance score of the patients during their follow-up period was 92.29+/-4.5 and 84.71+/-11.80 for the counseled and control group, respectively. Statistical analysis of medication knowledge was carried out and all the demographic characters and number of medication were individually correlated with medication knowledge score and the difference observed was statistically significant. Compliance score of the patients was 92.29+/-4.5 and 84.71+/-11.8 % for the counseled and usual care group, respectively.


Subject(s)
Counseling/standards , Drug Therapy/psychology , Patient Compliance/psychology , Patient Education as Topic/standards , Adult , Developing Countries , Drug Therapy/statistics & numerical data , Educational Status , Female , Follow-Up Studies , Health Knowledge, Attitudes, Practice , Hospitals, Private , Humans , India , Male , Middle Aged , Outpatient Clinics, Hospital , Patient Compliance/statistics & numerical data , Program Evaluation , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...